BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Huang K, Dahele M, Senan S, Guckenberger M, Rodrigues GB, Ward A, Boldt RG, Palma DA. Radiographic changes after lung stereotactic ablative radiotherapy (SABR)--can we distinguish recurrence from fibrosis? A systematic review of the literature. Radiother Oncol. 2012;102:335-342. [PMID: 22305958 DOI: 10.1016/j.radonc.2011.12.018] [Cited by in Crossref: 139] [Cited by in F6Publishing: 133] [Article Influence: 13.9] [Reference Citation Analysis]
Number Citing Articles
1 Al-umairi R, Tarique U, Moineddin R, Jimenez-juan L, Kha LC, Cheung P, Oikonomou A. CT patterns and serial CT Changes in lung Cancer patients post stereotactic body radiotherapy (SBRT). Cancer Imaging 2022;22. [DOI: 10.1186/s40644-022-00491-1] [Reference Citation Analysis]
2 Kim G, Moon S, Choi J. Deep Learning with Multimodal Integration for Predicting Recurrence in Patients with Non-Small Cell Lung Cancer. Sensors 2022;22:6594. [DOI: 10.3390/s22176594] [Reference Citation Analysis]
3 Yang H, Wang L, Shao G, Dong B, Wang F, Wei Y, Li P, Chen H, Chen W, Zheng Y, He Y, Zhao Y, Du X, Sun X, Wang Z, Wang Y, Zhou X, Lai X, Feng W, Shen L, Qiu G, Ji Y, Chen J, Jiang Y, Liu J, Zeng J, Wang C, Zhao Q, Yang X, Hu X, Ma H, Chen Q, Chen M, Jiang H, Xu Y. A combined predictive model based on radiomics features and clinical factors for disease progression in early-stage non-small cell lung cancer treated with stereotactic ablative radiotherapy. Front Oncol 2022;12:967360. [DOI: 10.3389/fonc.2022.967360] [Reference Citation Analysis]
4 Matsumoto Y. A pictorial essay on radiological changes after stereotactic body radiation therapy for lung tumors. Jpn J Radiol. [DOI: 10.1007/s11604-022-01252-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Sodji QH, Harris JP, Quon A, Modlin LA, Lau B, Jiang A, Trakul N, Maxim PG, Diehn M, Loo BW, Hiniker SM. Detection of Recurrence after Thoracic Stereotactic Ablative Radiotherapy Using FDG-PET-CT. Clinical Lung Cancer 2022. [DOI: 10.1016/j.cllc.2022.01.006] [Reference Citation Analysis]
6 Vaz SC, Adam JA, Bolton RCD, Vera P, van Elmpt W, Herrmann K, Hicks RJ, Lievens Y, Santos A, Schöder H, Dubray B, Visvikis D, Troost EGC, de Geus-Oei LF. Joint EANM/SNMMI/ESTRO practice recommendations for the use of 2-[18F]FDG PET/CT external beam radiation treatment planning in lung cancer V1.0. Eur J Nucl Med Mol Imaging 2022. [PMID: 35022844 DOI: 10.1007/s00259-021-05624-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
7 Lee K, Le T, Hau E, Hanna GG, Gee H, Vinod S, Dammak S, Palma D, Ong A, Yeghiaian-Alvandi R, Buck J, Lim R. A systematic review into the radiological features predicting local recurrence after stereotactic ablative body radiotherapy (SABR) in patients with non-small cell lung cancer (NSCLC): Local recurrence features of NSCLC post-SABR. Int J Radiat Oncol Biol Phys 2021:S0360-3016(21)03235-1. [PMID: 34879247 DOI: 10.1016/j.ijrobp.2021.11.027] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Qiu B, Guo W, Zhang F, Lv F, Ji Y, Peng Y, Chen X, Bao H, Xu Y, Shao Y, Tan F, Xue Q, Gao S, He J. Dynamic recurrence risk and adjuvant chemotherapy benefit prediction by ctDNA in resected NSCLC. Nat Commun 2021;12:6770. [PMID: 34799585 DOI: 10.1038/s41467-021-27022-z] [Cited by in F6Publishing: 11] [Reference Citation Analysis]
9 Hellbach K. [Modern tumor therapy and its pulmonary side effects]. Radiologe 2021;61:955-67. [PMID: 34550423 DOI: 10.1007/s00117-021-00912-5] [Reference Citation Analysis]
10 Ulrich B, Pradines A, Mazières J, Guibert N. Detection of Tumor Recurrence via Circulating Tumor DNA Profiling in Patients with Localized Lung Cancer: Clinical Considerations and Challenges. Cancers (Basel) 2021;13:3759. [PMID: 34359659 DOI: 10.3390/cancers13153759] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
11 Guerreiro NFC, Araujo-Filho JAB, Horvat N, Lee HJ, Oliveira BSP, Ynoe de Moraes F, Castro I, Miranda Degrande FA, Abreu CEV, Giassi KS. Interobserver Variability in the Computed Tomography Assessment of Pulmonary Injury and Tumor Recurrence After Stereotactic Body Radiotherapy. J Thorac Imaging 2020;35:302-8. [PMID: 32168165 DOI: 10.1097/RTI.0000000000000495] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Ikawa T, Tabuchi T, Konishi K, Morimoto M, Hirata T, Kanayama N, Wada K, Toratani M, Okawa S, Ogawa K, Teshima T. Prolonged overall treatment time negatively affects the outcomes of stereotactic body radiotherapy for early-stage non-small-cell lung cancer: A propensity score-weighted, single-center analysis. PLoS One 2021;16:e0253203. [PMID: 34143851 DOI: 10.1371/journal.pone.0253203] [Reference Citation Analysis]
13 Onishi H, Shioyama Y, Matsumoto Y, Shibamoto Y, Miyakawa A, Suzuki G, Nishimura Y, Sasaki R, Miyawaki D, Kuriyama K, Komiyama T, Marino K, Aoki S, Saito R, Araya M, Maehata Y, Nonaka H, Tominaga L, Saito M, Sano N, Yamada S. Stereotactic body radiotherapy in patients with lung tumors composed of mainly ground-glass opacity. J Radiat Res 2020;61:426-30. [PMID: 32219316 DOI: 10.1093/jrr/rraa015] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
14 Christensen TN, Langer SW, Persson G, Larsen KR, Loft A, Amtoft AG, Berthelsen AK, Johannesen HH, Keller SH, Kjaer A, Fischer BM. 18F-FLT PET/CT Adds Value to 18F-FDG PET/CT for Diagnosing Relapse After Definitive Radiotherapy in Patients with Lung Cancer: Results of a Prospective Clinical Trial. J Nucl Med 2021;62:628-35. [PMID: 33037090 DOI: 10.2967/jnumed.120.247742] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
15 Takemoto S, Shibamoto Y, Hashizume C, Miyakawa A, Murai T, Yanagi T, Sugie C, Nagai A. Changes in pulmonary function and their correlation with dose-volume parameters in patients undergoing stereotactic body radiotherapy for lung cancer. J Radiat Res 2021;62:338-45. [PMID: 33480428 DOI: 10.1093/jrr/rraa131] [Reference Citation Analysis]
16 Dong B, Zhu X, Shu Z, Ji Y, Lu F, Wang J, Chen M. Video-Assisted Thoracoscopic Lobectomy Versus Stereotactic Body Radiotherapy Treatment for Early-Stage Non-Small Cell Lung Cancer: A Propensity Score-Matching Analysis. Front Oncol 2020;10:585709. [PMID: 33244457 DOI: 10.3389/fonc.2020.585709] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
17 Dağdelen M, Akovalı ES, Barlas C, Can G, Dinçbaş FÖ. Interobserver agreement between interpretations of acute changes after lung stereotactic body radiotherapy. Strahlenther Onkol 2021;197:423-8. [PMID: 33231713 DOI: 10.1007/s00066-020-01711-y] [Reference Citation Analysis]
18 Dong B, Zhu X, Jin J, Chen Y, Ying H, Chen Y, Lu F, Shen W, Wang J, Chen M. Comparison of the outcomes of sublobar resection and stereotactic body radiotherapy for stage T1-2N0M0 non-small cell lung cancer with tumor size ≤ 5 cm: a propensity score matching analysis. J Thorac Dis 2020;12:5934-54. [PMID: 33209426 DOI: 10.21037/jtd-20-2367] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
19 Evison M, Barrett E, Cheng A, Mulla A, Walls G, Johnston D, McAleese J, Moore K, Hicks J, Blyth K, Denholm M, Magee L, Gilligan D, Silverman S, Hiley C, Qureshi M, Clinch H, Hatton M, Philipps L, Brown S, O'Brien M, McDonald F, Faivre-Finn C. Predicting the Risk of Disease Recurrence and Death Following Curative-intent Radiotherapy for Non-small Cell Lung Cancer: The Development and Validation of Two Scoring Systems From a Large Multicentre UK Cohort. Clin Oncol (R Coll Radiol) 2021;33:145-54. [PMID: 32978027 DOI: 10.1016/j.clon.2020.09.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
20 Tan D, Gill S, Loh N. Timing of fluorodeoxyglucose positron emission tomography maximum standardized uptake value for diagnosis of local recurrence of non-small cell lung cancer after stereotactic body radiation therapy. Cancer Med 2020;9:7469-76. [PMID: 32846054 DOI: 10.1002/cam4.3302] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
21 Yang WC, Hsu FM, Yang PC. Precision radiotherapy for non-small cell lung cancer. J Biomed Sci 2020;27:82. [PMID: 32693792 DOI: 10.1186/s12929-020-00676-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
22 Chassagnon G, Martini K, Giraud P, Revel MP. Radiological assessment after stereotactic body radiation of lung tumours. Cancer Radiother 2020;24:379-87. [PMID: 32534799 DOI: 10.1016/j.canrad.2020.04.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
23 Li Q, Liu Y, Su B, Zhao H, Lin Q, Zhu Y, Zhang L, Weng D, Gong X, Sun X, Xu Y. The CT appearance pattern of radiation-induced lung injury and tumor recurrence after stereotactic body radiation therapy in early stage non-small cell lung cancer. Transl Lung Cancer Res 2020;9:713-21. [PMID: 32676333 DOI: 10.21037/tlcr-20-609] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
24 Frerker B, Hildebrandt G. Distinguishing Radiation Pneumonitis from Local Tumour Recurrence Following SBRT for Lung Cancer

]]>. RMI 2020;Volume 13:1-23. [DOI: 10.2147/rmi.s176901] [Reference Citation Analysis]
25 Chin RI, Chen K, Usmani A, Chua C, Harris PK, Binkley MS, Azad TD, Dudley JC, Chaudhuri AA. Detection of Solid Tumor Molecular Residual Disease (MRD) Using Circulating Tumor DNA (ctDNA). Mol Diagn Ther 2019;23:311-31. [PMID: 30941670 DOI: 10.1007/s40291-019-00390-5] [Cited by in Crossref: 40] [Cited by in F6Publishing: 61] [Article Influence: 20.0] [Reference Citation Analysis]
26 Brooks ED, Verma V, Senan S, De Baere T, Lu S, Brunelli A, Chang JY; International Association for the Study of Lung Cancer Advanced Radiation Technology Committee. Salvage Therapy for Locoregional Recurrence After Stereotactic Ablative Radiotherapy for Early-Stage NSCLC. J Thorac Oncol 2020;15:176-89. [PMID: 31712134 DOI: 10.1016/j.jtho.2019.10.016] [Cited by in Crossref: 9] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
27 Dong B, Wang J, Zhu X, Chen Y, Xu Y, Shao K, Zheng L, Ying H, Chen M, Cao J. Comparison of the outcomes of stereotactic body radiotherapy versus surgical treatment for elderly (≥70) patients with early-stage non-small cell lung cancer after propensity score matching. Radiat Oncol 2019;14:195. [PMID: 31699115 DOI: 10.1186/s13014-019-1399-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
28 Connolly JG, Jones GD, Caso R, Jones DR. Stereotactic ablative radiotherapy for operable stage I non-small cell lung cancer: not ready for prime time. Ann Transl Med 2019;7:S234. [PMID: 31656813 DOI: 10.21037/atm.2019.08.40] [Reference Citation Analysis]
29 Halpenny D, O'Dwyer E, Camacho Vasquez J, Shaverdian N, Girshman J, Ginsberg MS. Imaging of Novel Oncologic Treatments in Lung Cancer Part 2: Local Ablative Therapies. J Thorac Imaging 2020;35:37-48. [PMID: 31592831 DOI: 10.1097/RTI.0000000000000452] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
30 Roy SF, Louie AV, Liberman M, Wong P, Bahig H. Pathologic response after modern radiotherapy for non-small cell lung cancer. Transl Lung Cancer Res 2019;8:S124-34. [PMID: 31673516 DOI: 10.21037/tlcr.2019.09.05] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
31 McAleese J, Taylor A, Walls GM, Hanna GG. Differential Relapse Patterns for Non-small Cell Lung Cancer Subtypes Adenocarcinoma and Squamous Cell Carcinoma: Implications for Radiation Oncology. Clin Oncol (R Coll Radiol) 2019;31:711-9. [PMID: 31351746 DOI: 10.1016/j.clon.2019.07.008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
32 Dubaere E, Goffaux M, Wanet M, Bihin B, Gheldof C, Demoulin AS, Bolly A, Bustin F, Duplaquet F, Baugnee PE, Gustin M, Hers V, Maisin F, Marchand E, Ocak S, Pirard L, Vancutsem O, Van Neck E, Vandermoten G, Zaharia L, Remouchamps V. Long term outcome after 48 Gy stereotactic ablative body radiotherapy for peripheral stage I non-small cell lung cancer. BMC Cancer 2019;19:639. [PMID: 31253136 DOI: 10.1186/s12885-019-5863-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
33 Hiniker SM, Sodji Q, Quon A, Gutkin PM, Arksey N, Graves EE, Chin FT, Maxim PG, Diehn M, Loo BW Jr. FLT-PET-CT for the Detection of Disease Recurrence After Stereotactic Ablative Radiotherapy or Hyperfractionation for Thoracic Malignancy: A Prospective Pilot Study. Front Oncol 2019;9:467. [PMID: 31214507 DOI: 10.3389/fonc.2019.00467] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
34 Li H, Verma V, Brooks ED, Feng L, Zhang T, Welsh JW, Lin SH, Gomez D, Gandhi S, Heymach JV, Chang JY. Impact of Corticosteroid Administration on Outcomes Following Stereotactic Ablative Radiotherapy for Non-small-cell Lung Cancer. Clin Lung Cancer 2019;20:e480-8. [PMID: 31078421 DOI: 10.1016/j.cllc.2019.03.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
35 Nakamura N, Hojo H, Inoue K, Hotta K, Zenda S, Baba H, Onozawa M, Motegi A, Nakamura M, Kibe Y, Akimoto T. Late radiological changes after passive scattering proton beam therapy for Stage I lung cancer. J Radiat Res 2018;59:456-61. [PMID: 29790995 DOI: 10.1093/jrr/rry028] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
36 Guckenberger M, Aerts JG, Van Schil P, Weder W. The American Society of Clinical Oncology-endorsed American Society for Radiation Oncology Evidence-Based Guideline of stereotactic body radiotherapy for early-stage non-small cell lung cancer: An expert opinion. J Thorac Cardiovasc Surg 2019;157:358-61. [PMID: 30557952 DOI: 10.1016/j.jtcvs.2018.09.107] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
37 Yang DM, Palma D, Louie A, Malthaner R, Fortin D, Rodrigues G, Yaremko B, Laba J, Gaede S, Warner A, Inculet R, Lee TY. Assessment of tumour response after stereotactic ablative radiation therapy for lung cancer: A prospective quantitative hybrid 18 F-fluorodeoxyglucose-positron emission tomography and CT perfusion study. J Med Imaging Radiat Oncol 2019;63:94-101. [PMID: 30281918 DOI: 10.1111/1754-9485.12807] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
38 Febbo JA, Gaddikeri RS, Shah PN. Stereotactic Body Radiation Therapy for Early-Stage Non–Small Cell Lung Cancer: A Primer for Radiologists. RadioGraphics 2018;38:1312-36. [DOI: 10.1148/rg.2018170155] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
39 Dickhoff C, Rodriguez Schaap PM, Otten RHJ, Heymans MW, Heineman DJ, Dahele M. Salvage surgery for local recurrence after stereotactic body radiotherapy for early stage non-small cell lung cancer: a systematic review. Ther Adv Med Oncol 2018;10:1758835918787989. [PMID: 30023008 DOI: 10.1177/1758835918787989] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
40 Frick MA, Kao GD, Aguarin L, Chinniah C, Swisher-McClure S, Berman AT, Levin WP, Cengel KA, DeCesaris C, Hahn SM, Dorsey JF, Simone CB 2nd. Circulating Tumor Cell Assessment in Presumed Early Stage Non-Small Cell Lung Cancer Patients Treated with Stereotactic Body Radiation Therapy: A Prospective Pilot Study. Int J Radiat Oncol Biol Phys 2018;102:536-42. [PMID: 30244877 DOI: 10.1016/j.ijrobp.2018.06.041] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
41 Raman S, Yau V, Pineda S, Le LW, Lau A, Bezjak A, Cho BCJ, Sun A, Hope AJ, Giuliani M. Ultracentral Tumors Treated With Stereotactic Body Radiotherapy: Single-Institution Experience. Clin Lung Cancer 2018;19:e803-10. [PMID: 30007498 DOI: 10.1016/j.cllc.2018.06.001] [Cited by in Crossref: 26] [Cited by in F6Publishing: 34] [Article Influence: 6.5] [Reference Citation Analysis]
42 Ronden MI, Palma D, Slotman BJ, Senan S. Brief Report on Radiological Changes following Stereotactic Ablative Radiotherapy (SABR) for Early-Stage Lung Tumors: A Pictorial Essay. Journal of Thoracic Oncology 2018;13:855-62. [DOI: 10.1016/j.jtho.2018.02.023] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
43 Kalman NS, Hugo GD, Kahn JM, Zhao SS, Jan N, Mahon RN, Weiss E. Interobserver reliability in describing radiographic lung changes after stereotactic body radiation therapy. Adv Radiat Oncol 2018;3:655-61. [PMID: 30370367 DOI: 10.1016/j.adro.2018.05.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
44 Mazzola R, Fersino S, Alongi P, Di Paola G, Gregucci F, Aiello D, Tebano U, Pasetto S, Ruggieri R, Salgarello M, Alongi F. Stereotactic body radiation therapy for liver oligometastases: predictive factors of local response by 18F-FDG-PET/CT. Br J Radiol 2018;91:20180058. [PMID: 29750538 DOI: 10.1259/bjr.20180058] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
45 Wang HH, Zhang CZ, Zhang BL, Chen J, Zeng XL, Deng L, Meng MB. Sublobar resection is associated with improved outcomes over radiotherapy in the management of high-risk elderly patients with Stage I non-small cell lung cancer: a systematic review and meta-analysis. Oncotarget 2017;8:6033-42. [PMID: 28002808 DOI: 10.18632/oncotarget.14010] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
46 Ronden M, van Sörnsen de Koste J, Johnson C, Slotman B, Spoelstra F, Haasbeek C, Blom G, Bongers E, Warner A, Ward A, Palma D, Senan S. Incidence of High-Risk Radiologic Features in Patients Without Local Recurrence After Stereotactic Ablative Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer. International Journal of Radiation Oncology*Biology*Physics 2018;100:115-21. [DOI: 10.1016/j.ijrobp.2017.09.035] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
47 Tyran M, Charrier N, Darreon J, Madroszyk A, Tallet A, Salem N. Early PET-CT After Stereotactic Radiotherapy for Stage 1 Non-small Cell Lung Carcinoma Is Predictive of Local Control. In Vivo 2018;32:121-4. [PMID: 29275308 DOI: 10.21873/invivo.11213] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
48 Frakulli R, Salvi F, Balestrini D, Palombarini M, Akshija I, Cammelli S, Morganti AG, Zompatori M, Frezza G. Radiological differential diagnosis between fibrosis and recurrence after stereotactic body radiation therapy (SBRT) in early stage non-small cell lung cancer (NSCLC). Transl Lung Cancer Res 2017;6:S1-7. [PMID: 29299403 DOI: 10.21037/tlcr.2017.10.01] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
49 Veiga C, Landau D, McClelland JR, Ledermann JA, Hawkes D, Janes SM, Devaraj A. Long term radiological features of radiation-induced lung damage. Radiother Oncol 2018;126:300-6. [PMID: 29191458 DOI: 10.1016/j.radonc.2017.11.003] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
50 Phillips I, Ajaz M, Ezhil V, Prakash V, Alobaidli S, McQuaid SJ, South C, Scuffham J, Nisbet A, Evans P. Clinical applications of textural analysis in non-small cell lung cancer. Br J Radiol 2018;91:20170267. [PMID: 28869399 DOI: 10.1259/bjr.20170267] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 3.6] [Reference Citation Analysis]
51 Li Q, Kim J, Balagurunathan Y, Qi J, Liu Y, Latifi K, Moros EG, Schabath MB, Ye Z, Gillies RJ, Dilling TJ. CT imaging features associated with recurrence in non-small cell lung cancer patients after stereotactic body radiotherapy. Radiat Oncol 2017;12:158. [PMID: 28946909 DOI: 10.1186/s13014-017-0892-y] [Cited by in Crossref: 39] [Cited by in F6Publishing: 44] [Article Influence: 7.8] [Reference Citation Analysis]
52 Chaudhuri AA, Chabon JJ, Lovejoy AF, Newman AM, Stehr H, Azad TD, Khodadoust MS, Esfahani MS, Liu CL, Zhou L, Scherer F, Kurtz DM, Say C, Carter JN, Merriott DJ, Dudley JC, Binkley MS, Modlin L, Padda SK, Gensheimer MF, West RB, Shrager JB, Neal JW, Wakelee HA, Loo BW, Alizadeh AA, Diehn M. Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling. Cancer Discov. 2017;7:1394-1403. [PMID: 28899864 DOI: 10.1158/2159-8290.cd-17-0716] [Cited by in Crossref: 273] [Cited by in F6Publishing: 362] [Article Influence: 54.6] [Reference Citation Analysis]
53 Awano N, Ikushima S, Izumo T, Tone M, Fukuda K, Miyamoto S, Bae Y, Kumasaka T, Terada Y, Furuhata Y, Nomura R, Sato K. Efficacy and safety of stereotactic body radiotherapy using CyberKnife in Stage I primary lung tumor. Japanese Journal of Clinical Oncology 2017;47:969-75. [DOI: 10.1093/jjco/hyx100] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
54 Nakagomi T, Goto T, Hirotsu Y, Shikata D, Amemiya K, Oyama T, Mochizuki H, Omata M. Elucidation of radiation-resistant clones by a serial study of intratumor heterogeneity before and after stereotactic radiotherapy in lung cancer. J Thorac Dis 2017;9:E598-604. [PMID: 28840024 DOI: 10.21037/jtd.2017.06.02] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
55 Guckenberger M, Andratschke N, Dieckmann K, Hoogeman MS, Hoyer M, Hurkmans C, Tanadini-lang S, Lartigau E, Méndez Romero A, Senan S, Verellen D. ESTRO ACROP consensus guideline on implementation and practice of stereotactic body radiotherapy for peripherally located early stage non-small cell lung cancer. Radiotherapy and Oncology 2017;124:11-7. [DOI: 10.1016/j.radonc.2017.05.012] [Cited by in Crossref: 115] [Cited by in F6Publishing: 145] [Article Influence: 23.0] [Reference Citation Analysis]
56 Kim K, Lee J, Cho Y, Chung SY, Lee JJB, Lee CG, Cho J. Predictive factors of symptomatic radiation pneumonitis in primary and metastatic lung tumors treated with stereotactic ablative body radiotherapy. Radiat Oncol J 2017;35:163-71. [PMID: 28712275 DOI: 10.3857/roj.2017.00066] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
57 Huang Y, Chen JL, Hsu F, Huang J, Ko W, Chen Y, Jaw F, Yen R, Chang Y. Response assessment of stereotactic body radiation therapy using dynamic contrast-enhanced integrated MR-PET in non-small cell lung cancer patients: Response Assessment of SBRT Using MR-PET. J Magn Reson Imaging 2018;47:191-9. [DOI: 10.1002/jmri.25758] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
58 Bouman-Wammes EW, van Dodewaard-De Jong JM, Dahele M, Cysouw MCF, Hoekstra OS, van Moorselaar RJA, Piet MAH, Verberne HJ, Bins AD, Verheul HMW, Slotman BJ, Oprea-Lager DE, Van den Eertwegh AJM. Benefits of Using Stereotactic Body Radiotherapy in Patients With Metachronous Oligometastases of Hormone-Sensitive Prostate Cancer Detected by [18F]fluoromethylcholine PET/CT. Clin Genitourin Cancer. 2017;15:e773-e782. [PMID: 28462855 DOI: 10.1016/j.clgc.2017.03.009] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 4.6] [Reference Citation Analysis]
59 Swaminath A, Wierzbicki M, Parpia S, Wright JR, Tsakiridis TK, Okawara GS, Kundapur V, Bujold A, Ahmed N, Hirmiz K, Kurien E, Filion E, Gabos Z, Faria S, Louie AV, Owen T, Wai E, Ramchandar K, Chan EK, Julian J, Cline K, Whelan TJ. Canadian Phase III Randomized Trial of Stereotactic Body Radiotherapy Versus Conventionally Hypofractionated Radiotherapy for Stage I, Medically Inoperable Non–Small-Cell Lung Cancer – Rationale and Protocol Design for the Ontario Clinical Oncology Group (OCOG)-LUSTRE Trial. Clinical Lung Cancer 2017;18:250-4. [DOI: 10.1016/j.cllc.2016.08.002] [Cited by in Crossref: 15] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
60 Palma DA, Nguyen TK, Kwan K, Gaede S, Landis M, Malthaner R, Fortin D, Louie AV, Frechette E, Rodrigues GB, Yaremko B, Yu E, Dar AR, Lee TY, Gratton A, Warner A, Ward A, Inculet R. Short report: interim safety results for a phase II trial measuring the integration of stereotactic ablative radiotherapy (SABR) plus surgery for early stage non-small cell lung cancer (MISSILE-NSCLC). Radiat Oncol. 2017;12:30. [PMID: 28129789 DOI: 10.1186/s13014-017-0770-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
61 Mazzola R, Fiorentino A, Di Paola G, Giaj Levra N, Ricchetti F, Fersino S, Tebano U, Pasetto S, Ruggieri R, Salgarello M, Alongi F. Stereotactic Ablative Radiation Therapy for Lung Oligometastases: Predictive Parameters of Early Response by 18FDG-PET/CT. J Thorac Oncol 2017;12:547-55. [PMID: 28126325 DOI: 10.1016/j.jtho.2016.11.2234] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
62 Nguyen TK, Palma DA. Pros: After stereotactic ablative radiotherapy for a peripheral early-stage non-small cell lung cancer, radiological suspicion of a local recurrence can be sufficient indication to proceed to salvage therapy. Transl Lung Cancer Res 2016;5:647-50. [PMID: 28151535 DOI: 10.21037/tlcr.2016.12.07] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
63 Ho QA, Harandi NK, Daly ME. Clinical Impact of Frequent Surveillance Imaging in the First Year Following Chemoradiation for Locally Advanced Non-small-cell Lung Cancer. Clin Lung Cancer 2017;18:410-4. [PMID: 28007410 DOI: 10.1016/j.cllc.2016.11.010] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
64 Loganadane G, Martinetti F, Mercier O, Krhili S, Riet F, Mbagui R, To H, Le Péchoux C, Levy A. Stereotactic ablative radiotherapy for early stage non-small cell lung cancer: A critical literature review of predictive factors of relapse. Cancer Treatment Reviews 2016;50:240-6. [DOI: 10.1016/j.ctrv.2016.10.002] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 4.3] [Reference Citation Analysis]
65 Peulen H, Mantel F, Guckenberger M, Belderbos J, Werner-wasik M, Hope A, Giuliani M, Grills I, Sonke J. Validation of High-Risk Computed Tomography Features for Detection of Local Recurrence After Stereotactic Body Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer. International Journal of Radiation Oncology*Biology*Physics 2016;96:134-41. [DOI: 10.1016/j.ijrobp.2016.04.003] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 3.7] [Reference Citation Analysis]
66 Ghaye B, Wanet M, El Hajjam M. Imaging after radiation therapy of thoracic tumors. Diagn Interv Imaging 2016;97:1037-52. [PMID: 27567554 DOI: 10.1016/j.diii.2016.06.019] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
67 Mattonen SA, Ward AD, Palma DA. Pulmonary imaging after stereotactic radiotherapy-does RECIST still apply? Br J Radiol 2016;89:20160113. [PMID: 27245137 DOI: 10.1259/bjr.20160113] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
68 Van den Begin R, Engels B, Boussaer M, Dhont J, Burghelea M, Depuydt T, Poels K, Collen C, Gevaert T, Verellen D, Storme G, de Mey J, De Ridder M. Motion management during SBRT for oligometastatic cancer: Results of a prospective phase II trial. Radiotherapy and Oncology 2016;119:519-24. [DOI: 10.1016/j.radonc.2016.04.020] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
69 Sawada S, Suehisa H, Ueno T, Sugimoto R, Yamashita M. Monitoring and management of lung cancer patients following curative-intent treatment: clinical utility of 2-deoxy-2-[fluorine-18]fluoro-d-glucose positron emission tomography/computed tomography. Lung Cancer (Auckl) 2016;7:45-51. [PMID: 28210160 DOI: 10.2147/LCTT.S83644] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
70 Navarro-Martin A, Aso S, Cacicedo J, Arnaiz M, Navarro V, Rosales S, de Blas R, Ramos R, Guedea F. Phase II Trial of SBRT for Stage I NSCLC: Survival, Local Control, and Lung Function at 36 Months. J Thorac Oncol. 2016;11:1101-1111. [PMID: 27103512 DOI: 10.1016/j.jtho.2016.03.021] [Cited by in Crossref: 30] [Cited by in F6Publishing: 36] [Article Influence: 5.0] [Reference Citation Analysis]
71 Mattonen SA, Palma DA, Johnson C, Louie AV, Landis M, Rodrigues G, Chan I, Etemad-rezai R, Yeung TP, Senan S, Ward AD. Detection of Local Cancer Recurrence After Stereotactic Ablative Radiation Therapy for Lung Cancer: Physician Performance Versus Radiomic Assessment. International Journal of Radiation Oncology*Biology*Physics 2016;94:1121-8. [DOI: 10.1016/j.ijrobp.2015.12.369] [Cited by in Crossref: 84] [Cited by in F6Publishing: 89] [Article Influence: 14.0] [Reference Citation Analysis]
72 Weller A, O'Brien MER, Ahmed M, Popat S, Bhosle J, McDonald F, Yap TA, Du Y, Vlahos I, deSouza NM. Mechanism and non-mechanism based imaging biomarkers for assessing biological response to treatment in non-small cell lung cancer. Eur J Cancer 2016;59:65-78. [PMID: 27016624 DOI: 10.1016/j.ejca.2016.02.017] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
73 Knoll MA, Salvatore M, Sheu RD, Knoll AD, Kerns SL, Lo YC, Rosenzweig KE. The use of isodose levels to interpret radiation induced lung injury: a quantitative analysis of computed tomography changes. Quant Imaging Med Surg 2016;6:35-41. [PMID: 26981453 DOI: 10.3978/j.issn.2223-4292.2016.02.07] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
74 Huang K, Palma DA; IASLC Advanced Radiation Technology Committee. Follow-up of patients after stereotactic radiation for lung cancer: a primer for the nonradiation oncologist. J Thorac Oncol 2015;10:412-9. [PMID: 25695219 DOI: 10.1097/JTO.0000000000000435] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 6.0] [Reference Citation Analysis]
75 Amini B, Beaman CB, Madewell JE, Allen PK, Rhines LD, Tatsui CE, Tannir NM, Li J, Brown PD, Ghia AJ. Osseous Pseudoprogression in Vertebral Bodies Treated with Stereotactic Radiosurgery: A Secondary Analysis of Prospective Phase I/II Clinical Trials. AJNR Am J Neuroradiol 2016;37:387-92. [PMID: 26494690 DOI: 10.3174/ajnr.A4528] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 4.7] [Reference Citation Analysis]
76 De Rose F, Cozzi L, Navarria P, Ascolese A, Clerici E, Infante M, Alloisio M, Testori A, Toschi L, Finocchiaro G, Santoro A, Scorsetti M. Clinical Outcome of Stereotactic Ablative Body Radiotherapy for Lung Metastatic Lesions in Non-small Cell Lung Cancer Oligometastatic Patients. Clinical Oncology 2016;28:13-20. [DOI: 10.1016/j.clon.2015.08.011] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 5.5] [Reference Citation Analysis]
77 Takenaka R, Shibamoto Y, Miyakawa A, Hashizume C, Baba F. The Fate of Residual Tumor Masses That Persist After Stereotactic Body Radiotherapy for Solitary Lung Nodules: Will They Recur? Clin Lung Cancer 2016;17:406-11. [PMID: 26781347 DOI: 10.1016/j.cllc.2015.12.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
78 Mattonen SA, Tetar S, Palma DA, Louie AV, Senan S, Ward AD. Imaging texture analysis for automated prediction of lung cancer recurrence after stereotactic radiotherapy. J Med Imaging (Bellingham) 2015;2:041010. [PMID: 26835492 DOI: 10.1117/1.JMI.2.4.041010] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.7] [Reference Citation Analysis]
79 Hamaji M, Chen F, Matsuo Y, Ueki N, Hiraoka M, Date H. Treatment and Prognosis of Isolated Local Relapse after Stereotactic Body Radiotherapy for Clinical Stage I Non-Small-Cell Lung Cancer. Journal of Thoracic Oncology 2015;10:1616-24. [DOI: 10.1097/jto.0000000000000662] [Cited by in Crossref: 29] [Cited by in F6Publishing: 33] [Article Influence: 4.1] [Reference Citation Analysis]
80 Bibault JE, Oudoux A, Durand-Labrunie J, Mirabel X, Lartigau É, Kolesnikov-Gauthier H. [Positron emission tomography and stereotactic body radiation therapy for lung cancer: From treatment planning to response evaluation]. Cancer Radiother 2015;19:790-4; quiz 795-9. [PMID: 26476702 DOI: 10.1016/j.canrad.2015.05.027] [Cited by in Crossref: 3] [Article Influence: 0.4] [Reference Citation Analysis]
81 Yamoah K, Showalter TN, Ohri N. Radiation Therapy Intensification for Solid Tumors: A Systematic Review of Randomized Trials. Int J Radiat Oncol Biol Phys. 2015;93:737-745. [PMID: 26530740 DOI: 10.1016/j.ijrobp.2015.07.2284] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 4.7] [Reference Citation Analysis]
82 Waissi W, Noël G, Giraud P. Surveillance après radiothérapie stéréotaxique des tumeurs pulmonaires. Cancer/Radiothérapie 2015;19:566-72. [DOI: 10.1016/j.canrad.2015.05.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
83 Dejima H, Matsutani N, Imazuru T, Morita S, Takahashi Y, Shimokawa T, Kawamura M. Combined Aortic Resection and Stent Graft Insertion for Local Recurrence of Metastatic Lung Carcinoma Following Stereotactic Radiotherapy: A Case Report. Ann Thorac Cardiovasc Surg 2016;22:52-6. [PMID: 26256818 DOI: 10.5761/atcs.cr.15-00079] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
84 Ceniceros L, Aristu J, Castañón E, Rolfo C, Legaspi J, Olarte A, Valtueña G, Moreno M, Gil-bazo I. Stereotactic body radiotherapy (SBRT) for the treatment of inoperable stage I non-small cell lung cancer patients. Clin Transl Oncol 2016;18:259-68. [DOI: 10.1007/s12094-015-1361-4] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
85 Verstegen NE, Lagerwaard FJ, Hashemi SM, Dahele M, Slotman BJ, Senan S. Patterns of Disease Recurrence after SABR for Early Stage Non–Small-Cell Lung Cancer: Optimizing Follow-Up Schedules for Salvage Therapy. Journal of Thoracic Oncology 2015;10:1195-200. [DOI: 10.1097/jto.0000000000000576] [Cited by in Crossref: 39] [Cited by in F6Publishing: 44] [Article Influence: 5.6] [Reference Citation Analysis]
86 Bibault JE, Mirabel X, Lacornerie T, Tresch E, Reynaert N, Lartigau E. Adapted Prescription Dose for Monte Carlo Algorithm in Lung SBRT: Clinical Outcome on 205 Patients. PLoS One 2015;10:e0133617. [PMID: 26207808 DOI: 10.1371/journal.pone.0133617] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
87 Raziee H, Hope A, Faruqi S, Yap ML, Roberts H, Kandel S, Le LW, Brade A, Cho J, Sun A, Bezjak A, Giuliani ME. Classification and Reporting of Late Radiographic Changes After Lung Stereotactic Body Radiotherapy: Proposing a New System. Clin Lung Cancer 2015;16:e245-51. [PMID: 26077096 DOI: 10.1016/j.cllc.2015.05.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
88 Franks K, Jain P, Snee M. Stereotactic Ablative Body Radiotherapy for Lung Cancer. Clinical Oncology 2015;27:280-9. [DOI: 10.1016/j.clon.2015.01.006] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
89 Adebahr S, Collette S, Shash E, Lambrecht M, Le Pechoux C, Faivre-Finn C, De Ruysscher D, Peulen H, Belderbos J, Dziadziuszko R, Fink C, Guckenberger M, Hurkmans C, Nestle U. LungTech, an EORTC Phase II trial of stereotactic body radiotherapy for centrally located lung tumours: a clinical perspective. Br J Radiol 2015;88:20150036. [PMID: 25873481 DOI: 10.1259/bjr.20150036] [Cited by in Crossref: 52] [Cited by in F6Publishing: 64] [Article Influence: 7.4] [Reference Citation Analysis]
90 Roesch J, Andratschke N, Guckenberger M. SBRT in operable early stage lung cancer patients. Transl Lung Cancer Res 2014;3:212-24. [PMID: 25806303 DOI: 10.3978/j.issn.2218-6751.2014.08.06] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
91 Bratman SV, Newman AM, Alizadeh AA, Diehn M. Potential clinical utility of ultrasensitive circulating tumor DNA detection with CAPP-Seq. Expert Rev Mol Diagn. 2015;15:715-719. [PMID: 25773944 DOI: 10.1586/14737159.2015.1019476] [Cited by in Crossref: 48] [Cited by in F6Publishing: 56] [Article Influence: 6.9] [Reference Citation Analysis]
92 Hayashi S, Tanaka H, Hoshi H. Imaging characteristics of local recurrences after stereotactic body radiation therapy for stage I non-small cell lung cancer: Evaluation of mass-like fibrosis. Thorac Cancer 2015;6:186-93. [PMID: 26273357 DOI: 10.1111/1759-7714.12162] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
93 Arcangeli S, Agolli L, Portalone L, Migliorino MR, Lopergolo MG, Monaco A, Dognini J, Pressello MC, Bracci S, Donato V. Patterns of CT lung injury and toxicity after stereotactic radiotherapy delivered with helical tomotherapy in early stage medically inoperable NSCLC. Br J Radiol 2015;88:20140728. [PMID: 25645106 DOI: 10.1259/bjr.20140728] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
94 Brada M, Pope A, Baumann M. SABR in NSCLC – The beginning of the end or the end of the beginning? Radiotherapy and Oncology 2015;114:135-7. [DOI: 10.1016/j.radonc.2015.01.012] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.7] [Reference Citation Analysis]
95 Zeng J, Baik C, Bhatia S, Mayr N, Rengan R. Combination of stereotactic ablative body radiation with targeted therapies. Lancet Oncol 2014;15:e426-34. [PMID: 25186046 DOI: 10.1016/S1470-2045(14)70026-9] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 3.9] [Reference Citation Analysis]
96 Chehade S, Palma DA. Stereotactic radiotherapy for early lung cancer: Evidence-based approach and future directions. Rep Pract Oncol Radiother 2015;20:403-10. [PMID: 26696779 DOI: 10.1016/j.rpor.2014.11.007] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
97 Navarria P, De Rose F, Ascolese AM. SBRT for lung oligometastases: Who is the perfect candidate? Rep Practical Oncol Radiother. 2014;. [PMID: 26696785 DOI: 10.1016/j.rpor.2014.11.005] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
98 Mattonen SA, Palma DA, Haasbeek CJ, Senan S, Ward AD. Early prediction of tumor recurrence based on CT texture changes after stereotactic ablative radiotherapy (SABR) for lung cancer. Med Phys 2014;41:033502. [PMID: 24593744 DOI: 10.1118/1.4866219] [Cited by in Crossref: 62] [Cited by in F6Publishing: 66] [Article Influence: 7.8] [Reference Citation Analysis]
99 Vulquin N, Feutray S, Peignaux-casasnovas K, Humbert O, Créhange G, Truc G, Maingon P, Martin É. Évaluation radiologique de la réponse tumorale après radiothérapie pulmonaire en conditions stéréotaxiques. Cancer/Radiothérapie 2014;18:414-9. [DOI: 10.1016/j.canrad.2014.07.157] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
100 Matsuo Y, Chen F, Hamaji M, Kawaguchi A, Ueki N, Nagata Y, Sonobe M, Morita S, Date H, Hiraoka M. Comparison of long-term survival outcomes between stereotactic body radiotherapy and sublobar resection for stage I non-small-cell lung cancer in patients at high risk for lobectomy: A propensity score matching analysis. Eur J Cancer 2014;50:2932-8. [PMID: 25281527 DOI: 10.1016/j.ejca.2014.09.006] [Cited by in Crossref: 59] [Cited by in F6Publishing: 70] [Article Influence: 7.4] [Reference Citation Analysis]
101 Yamashita H, Takahashi W, Haga A, Nakagawa K. Radiation pneumonitis after stereotactic radiation therapy for lung cancer. World J Radiol 2014; 6(9): 708-715 [PMID: 25276313 DOI: 10.4329/wjr.v6.i9.708] [Cited by in CrossRef: 57] [Cited by in F6Publishing: 52] [Article Influence: 7.1] [Reference Citation Analysis]
102 Kishan AU, Wang PC, Sheng K, Yu V, Ruan D, Cao M, Tenn S, Low DA, Lee P. Correlation of Clinical and Dosimetric Parameters With Radiographic Lung Injury Following Stereotactic Body Radiotherapy. Technol Cancer Res Treat 2015;14:411-8. [PMID: 25261069 DOI: 10.1177/1533034614551476] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
103 Dorsey JF, Kao GD, MacArthur KM, Ju M, Steinmetz D, Wileyto EP, Simone CB 2nd, Hahn SM. Tracking viable circulating tumor cells (CTCs) in the peripheral blood of non-small cell lung cancer (NSCLC) patients undergoing definitive radiation therapy: pilot study results. Cancer 2015;121:139-49. [PMID: 25241991 DOI: 10.1002/cncr.28975] [Cited by in Crossref: 67] [Cited by in F6Publishing: 77] [Article Influence: 8.4] [Reference Citation Analysis]
104 Iizuka Y, Matsuo Y, Umeoka S, Nakamoto Y, Ueki N, Mizowaki T, Togashi K, Hiraoka M. Prediction of clinical outcome after stereotactic body radiotherapy for non-small cell lung cancer using diffusion-weighted MRI and (18)F-FDG PET. Eur J Radiol 2014;83:2087-92. [PMID: 25174774 DOI: 10.1016/j.ejrad.2014.07.018] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.8] [Reference Citation Analysis]
105 Faruqi S, Giuliani ME, Raziee H, Yap ML, Roberts H, Le LW, Brade A, Cho J, Sun A, Bezjak A, Hope AJ. Interrater Reliability of the Categorization of Late Radiographic Changes After Lung Stereotactic Body Radiation Therapy. International Journal of Radiation Oncology*Biology*Physics 2014;89:1076-83. [DOI: 10.1016/j.ijrobp.2014.04.042] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
106 Barillot I, Munier O, Hatime M, Mornex F. Stratégies d’évaluation de la réponse après irradiation stéréotaxique des cancers bronchiques primitifs et des métastases pulmonaires. Cancer/Radiothérapie 2014;18:308-12. [DOI: 10.1016/j.canrad.2013.12.010] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
107 Palma DA, Salama JK, Lo SS, Senan S, Treasure T, Govindan R, Weichselbaum R. The oligometastatic state - separating truth from wishful thinking. Nat Rev Clin Oncol 2014;11:549-57. [PMID: 24958182 DOI: 10.1038/nrclinonc.2014.96] [Cited by in Crossref: 161] [Cited by in F6Publishing: 180] [Article Influence: 20.1] [Reference Citation Analysis]
108 Mattonen SA, Huang K, Ward AD, Senan S, Palma DA. New techniques for assessing response after hypofractionated radiotherapy for lung cancer. J Thorac Dis 2014;6:375-86. [PMID: 24688782 DOI: 10.3978/j.issn.2072-1439.2013.11.09] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
109 Sahiner I, Vural GU. Positron emission tomography/computerized tomography in lung cancer. Quant Imaging Med Surg 2014;4:195-206. [PMID: 24914421 DOI: 10.3978/j.issn.2223-4292.2014.03.05] [Cited by in F6Publishing: 10] [Reference Citation Analysis]
110 Hayashi S, Tanaka H, Kajiura Y, Ohno Y, Hoshi H. Stereotactic body radiotherapy for very elderly patients (age, greater than or equal to 85 years) with stage I non-small cell lung cancer. Radiat Oncol 2014;9:138. [PMID: 24935216 DOI: 10.1186/1748-717X-9-138] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 4.0] [Reference Citation Analysis]
111 Tarasevych S, Lauwers P, Vandaele F, van Meerbeeck JP. Novel treatment options in stage I non-small-cell lung cancer. Expert Rev Anticancer Ther 2014;14:1007-20. [PMID: 24930519 DOI: 10.1586/14737140.2014.929500] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
112 Frechette KM, Brown LC, Aubry MC, Wigle DA, Olivier KR. Pseudoprogression after Stereotactic Body Radiotherapy. Journal of Thoracic Oncology 2014;9:e29-30. [DOI: 10.1097/jto.0000000000000067] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
113 Takahashi W, Nakajima M, Yamamoto N, Yamada S, Yamashita H, Nakagawa K, Tsuji H, Kamada T. Carbon ion radiotherapy for oligo-recurrent lung metastases from colorectal cancer: a feasibility study. Radiat Oncol 2014;9:68. [PMID: 24581481 DOI: 10.1186/1748-717X-9-68] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
114 Peulen H, Belderbos J, Rossi M, Sonke J. Mid-ventilation based PTV margins in Stereotactic Body Radiotherapy (SBRT): A clinical evaluation. Radiotherapy and Oncology 2014;110:511-6. [DOI: 10.1016/j.radonc.2014.01.010] [Cited by in Crossref: 46] [Cited by in F6Publishing: 50] [Article Influence: 5.8] [Reference Citation Analysis]
115 Vansteenkiste J, Crinò L, Dooms C, Douillard JY, Faivre-Finn C, Lim E, Rocco G, Senan S, Van Schil P, Veronesi G, Stahel R, Peters S, Felip E; Panel Members. 2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up. Ann Oncol 2014;25:1462-74. [PMID: 24562446 DOI: 10.1093/annonc/mdu089] [Cited by in Crossref: 223] [Cited by in F6Publishing: 271] [Article Influence: 27.9] [Reference Citation Analysis]
116 Kirkpatrick JP, Kelsey CR, Palta M, Cabrera AR, Salama JK, Patel P, Perez BA, Lee J, Yin FF. Stereotactic body radiotherapy: a critical review for nonradiation oncologists. Cancer 2014;120:942-54. [PMID: 24382744 DOI: 10.1002/cncr.28515] [Cited by in Crossref: 52] [Cited by in F6Publishing: 47] [Article Influence: 5.8] [Reference Citation Analysis]
117 Shirvani SM, Chang JY, Roth JA. Can stereotactic ablative radiotherapy in early stage lung cancers produce comparable success as surgery? Thorac Surg Clin 2013;23:369-81. [PMID: 23931020 DOI: 10.1016/j.thorsurg.2013.05.009] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
118 Rubio C, Morera R, Hernando O, Leroy T, Lartigau SE. Extracranial stereotactic body radiotherapy. Review of main SBRT features and indications in primary tumors. Rep Pract Oncol Radiother 2013;18:387-96. [PMID: 24416584 DOI: 10.1016/j.rpor.2013.09.009] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 4.3] [Reference Citation Analysis]
119 Guckenberger M, Klement RJ, Allgäuer M, Appold S, Dieckmann K, Ernst I, Ganswindt U, Holy R, Nestle U, Nevinny-stickel M, Semrau S, Sterzing F, Wittig A, Andratschke N, Flentje M. Applicability of the linear-quadratic formalism for modeling local tumor control probability in high dose per fraction stereotactic body radiotherapy for early stage non-small cell lung cancer. Radiotherapy and Oncology 2013;109:13-20. [DOI: 10.1016/j.radonc.2013.09.005] [Cited by in Crossref: 72] [Cited by in F6Publishing: 76] [Article Influence: 8.0] [Reference Citation Analysis]
120 Huang K, Senthi S, Palma DA, Spoelstra FO, Warner A, Slotman BJ, Senan S. High-risk CT features for detection of local recurrence after stereotactic ablative radiotherapy for lung cancer. Radiotherapy and Oncology 2013;109:51-7. [DOI: 10.1016/j.radonc.2013.06.047] [Cited by in Crossref: 83] [Cited by in F6Publishing: 85] [Article Influence: 9.2] [Reference Citation Analysis]
121 Senthi S, Dahele M, van de Ven PM, Slotman BJ, Senan S. Late radiologic changes after stereotactic ablative radiotherapy for early stage lung cancer: A comparison of fixed-beam versus arc delivery techniques. Radiotherapy and Oncology 2013;109:77-81. [DOI: 10.1016/j.radonc.2013.08.034] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
122 Guckenberger M, Andratschke N, Alheit H, Holy R, Moustakis C, Nestle U, Sauer O; Deutschen Gesellschaft für Radioonkologie (DEGRO). Definition of stereotactic body radiotherapy: principles and practice for the treatment of stage I non-small cell lung cancer. Strahlenther Onkol 2014;190:26-33. [PMID: 24052011 DOI: 10.1007/s00066-013-0450-y] [Cited by in Crossref: 112] [Cited by in F6Publishing: 120] [Article Influence: 12.4] [Reference Citation Analysis]
123 Guckenberger M, Allgäuer M, Appold S, Dieckmann K, Ernst I, Ganswindt U, Holy R, Nestle U, Nevinny-stickel M, Semrau S, Sterzing F, Wittig A, Andratschke N. Safety and Efficacy of Stereotactic Body Radiotherapy for Stage I Non–Small-Cell Lung Cancer in Routine Clinical Practice: A Patterns-of-Care and Outcome Analysis. Journal of Thoracic Oncology 2013;8:1050-8. [DOI: 10.1097/jto.0b013e318293dc45] [Cited by in Crossref: 132] [Cited by in F6Publishing: 131] [Article Influence: 14.7] [Reference Citation Analysis]
124 Stauder MC, Rooney JW, Neben-Wittich MA, Garces YI, Olivier KR. Late tumor pseudoprogression followed by complete remission after lung stereotactic ablative radiotherapy. Radiat Oncol 2013;8:167. [PMID: 23829565 DOI: 10.1186/1748-717X-8-167] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
125 Widder J, Klinkenberg TJ, Ubbels JF, Wiegman EM, Groen HJ, Langendijk JA. Pulmonary oligometastases: metastasectomy or stereotactic ablative radiotherapy? Radiother Oncol. 2013;107:409-413. [PMID: 23773410 DOI: 10.1016/j.radonc.2013.05.024] [Cited by in Crossref: 75] [Cited by in F6Publishing: 82] [Article Influence: 8.3] [Reference Citation Analysis]
126 Griffioen GH, Lagerwaard FJ, Haasbeek CJ, Smit EF, Slotman BJ, Senan S. Treatment of multiple primary lung cancers using stereotactic radiotherapy, either with or without surgery. Radiotherapy and Oncology 2013;107:403-8. [DOI: 10.1016/j.radonc.2013.04.026] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 2.4] [Reference Citation Analysis]
127 Mattonen SA, Palma DA, Haasbeek CJ, Senan S, Ward AD. Distinguishing radiation fibrosis from tumour recurrence after stereotactic ablative radiotherapy (SABR) for lung cancer: a quantitative analysis of CT density changes. Acta Oncol 2013;52:910-8. [PMID: 23106174 DOI: 10.3109/0284186X.2012.731525] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 4.6] [Reference Citation Analysis]
128 Verstegen NE, Lagerwaard FJ, Senan S. Developments in early-stage NSCLC: advances in radiotherapy. Ann Oncol 2012;23 Suppl 10:x46-51. [PMID: 22987992 DOI: 10.1093/annonc/mds301] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
129 Nakajima N, Sugawara Y, Kataoka M, Hamamoto Y, Ochi T, Sakai S, Takahashi T, Kajihara M, Teramoto N, Yamashita M, Mochizuki T. Differentiation of tumor recurrence from radiation-induced pulmonary fibrosis after stereotactic ablative radiotherapy for lung cancer: characterization of 18F-FDG PET/CT findings. Ann Nucl Med 2013;27:261-70. [PMID: 23299492 DOI: 10.1007/s12149-012-0682-4] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 3.7] [Reference Citation Analysis]
130 Takeda A, Kunieda E, Fujii H, Yokosuka N, Aoki Y, Oooka Y, Oku Y, Ohashi T, Sanuki N, Mizuno T, Ozawa Y. Evaluation for local failure by 18F-FDG PET/CT in comparison with CT findings after stereotactic body radiotherapy (SBRT) for localized non-small-cell lung cancer. Lung Cancer 2013;79:248-53. [PMID: 23246123 DOI: 10.1016/j.lungcan.2012.11.008] [Cited by in Crossref: 42] [Cited by in F6Publishing: 41] [Article Influence: 4.2] [Reference Citation Analysis]
131 Guckenberger M, Klement RJ, Kestin LL, Hope AJ, Belderbos J, Werner-Wasik M, Yan D, Sonke JJ, Bissonnette JP, Xiao Y. Lack of a dose-effect relationship for pulmonary function changes after stereotactic body radiation therapy for early-stage non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2013;85:1074-1081. [PMID: 23154077 DOI: 10.1016/j.ijrobp.2012.09.016] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 3.6] [Reference Citation Analysis]
132 Takahashi W, Yamashita H, Niibe Y, Shiraishi K, Hayakawa K, Nakagawa K. Stereotactic body radiotherapy for metastatic lung cancer as oligo-recurrence: an analysis of 42 cases. Pulm Med 2012;2012:454107. [PMID: 23094150 DOI: 10.1155/2012/454107] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
133 Senthi S, Lagerwaard FJ, Haasbeek CJ, Slotman BJ, Senan S. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis. The Lancet Oncology 2012;13:802-9. [DOI: 10.1016/s1470-2045(12)70242-5] [Cited by in Crossref: 284] [Cited by in F6Publishing: 296] [Article Influence: 28.4] [Reference Citation Analysis]